Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL.
Lukashev M, et al.
Cancer Res. 2006 Oct 1;66(19):9617-24. doi: 10.1158/0008-5472.CAN-06-0217.
Cancer Res. 2006.
PMID: 17018619